---
title: "Akoya Biosciences | 8-K: FY2025 Q1 Revenue Misses Estimate at USD 16.64 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239903264.md"
datetime: "2025-05-12T20:11:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239903264.md)
  - [en](https://longbridge.com/en/news/239903264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239903264.md)
generator: "portal-rs"
---

# Akoya Biosciences | 8-K: FY2025 Q1 Revenue Misses Estimate at USD 16.64 M

Revenue: As of FY2025 Q1, the actual value is USD 16.64 M, missing the estimate of USD 19.3 M.

EPS: As of FY2025 Q1, the actual value is USD -0.32, missing the estimate of USD -0.2071.

EBIT: As of FY2025 Q1, the actual value is USD -15.6 M.

### Revenue

-   Total revenue for the first quarter of 2025 was $16.6 million, a decrease of 9.8% compared to $18.4 million in the prior year period.

### Gross Margin

-   Gross margin improved to 59.3% in the first quarter of 2025, compared to 45.7% in the prior year period.

### Operating Expenses

-   Operating expenses were $23.3 million for the first quarter of 2025, a reduction of 22.3% from $30.0 million in the prior year period.

### Operating Loss

-   Operating loss was $13.4 million for the first quarter of 2025, an improvement of 37.9% compared to $21.6 million in the prior year period.

### Net Cash Used in Operating Activities

-   Net cash used in operating activities decreased by $13.6 million to $7.2 million in the first quarter of 2025, compared to $20.8 million in the prior year period.

### Cash, Cash Equivalents, and Marketable Securities

-   As of March 31, 2025, Akoya had $27.5 million in cash, cash equivalents, and marketable securities.

### Unique Metrics

-   The installed base of instruments increased by 12.0% year-over-year, ending the quarter with 1,359 instruments (410 PhenoCyclers, 949 PhenoImagers).
-   Total publications citing Akoya’s technology increased by 44.7% year-over-year, reaching 1,891 publications.

### Outlook / Guidance

-   Akoya will not be hosting an earnings conference call or providing forward-looking guidance due to the pending acquisition by Quanterix Corporation.

### Related Stocks

- [AKYA.US](https://longbridge.com/en/quote/AKYA.US.md)

## Related News & Research

- [QTRX: Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024](https://longbridge.com/en/news/295698010.md)
- [Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary](https://longbridge.com/en/news/295409153.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**